Neuropeptide Y

Summary

Neuropeptide Y is a 36-amino acid endogenous neuropeptide widely expressed in the central and peripheral nervous systems. It is one of the most abundant neuropeptides in the brain and plays key roles in appetite stimulation, energy balance, stress response, vasoconstriction, and modulation of anxiety and mood. It is not approved as a therapeutic agent but is extensively studied as a research tool and potential drug target.

Mechanism of Action

Neuropeptide Y (NPY) acts as an agonist at G-protein coupled NPY receptors (Y1, Y2, Y4, Y5, and Y6 subtypes), inhibiting adenylyl cyclase and modulating intracellular calcium. It regulates food intake (orexigenic), energy homeostasis, cardiovascular tone (vasoconstriction), anxiety, circadian rhythms, and neurogenesis.

Routes of Administration

Goals & Uses

• Circadian rhythm regulationChronobiology ResearchLow
• Cardiovascular regulationCardiovascular ResearchModerate
• Epilepsy / Seizure suppressionNeurology ResearchModerate
• Appetite stimulation / Orexigenic researchMetabolic / Obesity ResearchHigh
• Anxiety and stress modulationNeuropsychiatric ResearchModerate
• Bone metabolismMusculoskeletal ResearchLow

Contraindications

• Hypertensive crisis riskCardiovascularHigh
• Known hypersensitivity to NPYImmunologicHigh

Adverse Effects

• Injection site reactionsLocalCommon
• Increased appetite / HyperphagiaMetabolicCommon
• Sedation / AnxiolysisNeurologicalUncommon
• Vasoconstriction / HypertensionCardiovascularCommon
• BradycardiaCardiovascularUncommon

Drug Interactions

• Antihypertensive agentsModerate
• DPP-IV inhibitors (e.g., sitagliptin)Low
• Sympathomimetic agents (e.g., norepinephrine)Moderate

Population Constraints

• Pediatric populationsAgeRelative
• Patients with cardiovascular diseaseComorbidityRelative
• Obese individualsMetabolicRelative
• Pregnant womenReproductiveRelative

Regulatory Status

• European UnionUnapprovedNot approved by EMA. Research compound only.
• United StatesUnapprovedNPY is not FDA-approved as a therapeutic. Used only in preclinical and clinical research studies.
• United KingdomUnapprovedNot approved by MHRA. Research compound only.

NPY itself is not approved by the FDA, EMA, or MHRA as a therapeutic drug. It is used as a research tool compound. Various NPY receptor agonists and antagonists are under investigation for obesity, anxiety, cardiovascular disease, and epilepsy.

Evidence & Sources

No sources recorded yet.